Syndromes - Stocks of the Day

Stocks of the Day

Sign In / Sign Up

Latest News
Stock Screener
AI Signals
News Archive
Membership
About
- About
- FAQ
- Blog
- Contact Us

Home
Latest News
Stock Screener
AI Signals
News Archive
Membership
About
- About
- FAQ
- Blog
- Contact Us

Register Free
Sign in

Search mobile

Topic :

Syndromes

NASDAQ, STTK

#Discontinuation #Financial Data #Letter to Shareholders #Syndromes

Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates

February 23, 2023
16:30

EST

– Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer – – Dosed patients in first combination cohort with azacitidine in ongoing Phase 1A/B clinical trial of SL-172154 in acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) – – Announced two

No Comments

NASDAQ, NURO

#Negative Financials #Syndromes #Trending News

NeuroMetrix Reports Q4 and Full Year 2022 Financial Results

February 23, 2023
07:00

EST

WOBURN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) — NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2022. The Company’s mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through

No Comments

FIXX, NASDAQ

#Event #New Clinical Trial Data #Syndromes #Trending News

Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium™ Meeting

February 22, 2023
16:01

EST

Preclinical Studies Demonstrated a Targeted Immunosuppression Approach Led to Reduced Immune Response to AAVHSC Administration and Improved Gene Expression In Vivo Gene Therapy Candidate HMI-204 for MLD Showed Robust CNS Distribution and Expression with Improved Packaging Productivity BEDFORD, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq:

No Comments

NASDAQ, RGNX

#Positive Clinical Trial Results #Syndromes #Trending News

Additional Positive Interim Data from Phase I/II/III CAMPSIITE™ Trial of REGENXBIO’s RGX-121 for the Treatment of MPS II (Hunter Syndrome) Presented at 19th Annual WORLDSymposiumTM

February 22, 2023
15:00

EST

RGX-121, a potential one-time gene therapy for the treatment of MPS II, continues to be well-tolerated with no drug-related SAEs across three dose levels Additional data from patients in Cohort 3 using pivotal program dose level continue to demonstrate largest reductions in CSF GAGs, continuing to approach normal levels

No Comments

NASDAQ, SNSE

#New Clinical Trial Data #Syndromes #Trending News

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

February 21, 2023
07:30

EST

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, presented preclinical data on SNS-101, a conditionally active, pH-selective VISTA-blocking antibody, in an oral presentation at Next Generation Antibody Therapeutics: From Discovery

No Comments

NASDAQ, PHAR

#New Clinical Trial Data #Syndromes #Trending News

Pharming announces first patient enrolled in pediatric clinical trial of leniolisib

February 21, 2023
01:00

EST

The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency LEIDEN, Netherlands, Feb. 21, 2023 /PRNewswire/ — Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM)/(Nasdaq: PHAR) announces that the first patient has been enrolled in its

No Comments

JSPR, NASDAQ

#Merger #New Employee #Syndromes

Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of Directors

February 17, 2023
08:20

EST

REDWOOD CITY, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell

No Comments

JSPR, NASDAQ

#Event #New Clinical Trial Data #Syndromes #Trending News

Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTR

February 17, 2023
08:10

EST

Both Fanconi Anemia patients treated with briquilimab successfully engrafted with neutrophil engraftment within 11 days 100% total donor chimerism was achieved through six months for the first patient and through three months for the second patient Both patients are doing well post-transplant with briquilimab-based conditioning REDWOOD CITY, Calif., Feb.

No Comments

NASDAQ, RGNX

#New Clinical Trial Data #Syndromes #Trending News

REGENXBIO Announces Presentations at the 19th Annual WORLDSymposium™ 2023

February 17, 2023
07:05

EST

New interim data from Phase I/I/III trial of RGX-121 for the treatment of MPS II and Phase I/II trial of RGX-111 for the treatment of MPS I to be presented ROCKVILLE, Md., Feb. 17, 2023 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral and eight poster

No Comments

JSPR, NASDAQ

#Featured #Positive Clinical Trial Results #Syndromes #Trending News

Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease Patients

February 16, 2023
16:05

EST

First two sickle cell disease participants have achieved 100% donor myeloid chimerism through 100 days follow-up Third sickle cell disease participant has now achieved 100% donor myeloid chimerism through 30 days follow-up All three participants have increased their hemoglobin at last follow-up relative to baseline REDWOOD CITY, Calif., Feb.

No Comments

< Page1 Page2 Page3 … Page58 >

Trending News

ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland

02/24/2023

Tactile Systems Technology, Inc. Announces Pricing of $32.5 Million Public Offering of Common Stock

02/23/2023

Gatos Silver Announces 2023 Production and Cost Guidance

02/23/2023

Columbia Banking System Set to Join S&P MidCap 400; Verra Mobility to Join S&P SmallCap 600

02/23/2023

MasTec Announces Fourth Quarter and Annual 2022 Financial Results

02/23/2023

Most read news

DelphX Announces Non-Brokered Unit Financing

02/22/2023

NIO’s F4 plant will be located in Chuzhou to produce models for Firefly sub-brand, report says

02/20/2023

Helix Reports Fourth Quarter and Full Year 2022 Results

02/20/2023

© 2022 stocksoftheday.

Stocks of the Day does not provide investment advice. All rights reserved.

Tools

Predictions
Stock Screener
News Archive
News Feed
News Tags
Tickers
Trending Tickers
News Sentiments
Holidays & Trading Hours

Learn

FAQ
Guides
Infographics
Affiliate Program FAQ

Account

Sign In
Register
Email Preferences
Membership Option

Company

About
Contact Us
Careers
Blog
Privacy Policy
Terms of Use
Sitemap

Partnerships

Affiliate Program
Partnerships

Create account

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

First Name

Last Name

Email

Password

I agree with the Terms of Use and Privacy Policy.

Already have an account?

Sign In

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

Email

Password

Remember me

Lost your password?

Not registered yet?

Create a free account

Sign In

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

Email

Password

Remember me

Lost your password?

Not registered yet?

Create a free account